Tremeau Pharmaceuticals
Cambridge, US · Founded 2016 · Delaware corporation · 1 employees on LinkedIn · 1 known investors
Tremeau develops non-opioid pain therapies for patient populations with high unmet medical needs. The company focuses on treatments for people living with pain.
Founders & leadership
Tremeau Pharmaceuticals was founded in 2016 by Bradford C. Sippy.
Investors · 1
Reported raises · per SEC filings
Form D private placements$5.2M disclosed across 1 round · 2016
▶$5.2MraisedFeb 2018 · 59 investors · PharmaceuticalsRule 506(b)
▶$5.2MraisedFeb 2018 · 59 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Benjamin EnersonExecutive Officer
- Mark CorriganExecutive Officer
- Bradford C. SippyExecutive Officer, Director
- Offering amount
- $5.2M
- Amount sold
- $5.2M
- Minimum investment
- $10K
- First sale
- Oct 2016
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Tremeau Pharmaceuticals do?
- Tremeau develops non-opioid pain therapies for patient populations with high unmet medical needs. The company focuses on treatments for people living with pain.
- Who founded Tremeau Pharmaceuticals?
- Tremeau Pharmaceuticals was founded by Bradford C. Sippy in 2016.
- Who are Tremeau Pharmaceuticals's investors?
- Tremeau Pharmaceuticals's investors include Gurnet Point Capital.
- How much funding has Tremeau Pharmaceuticals raised?
- Tremeau Pharmaceuticals has disclosed $5.2M raised across 1 round.
- Where is Tremeau Pharmaceuticals headquartered?
- Tremeau Pharmaceuticals is headquartered in Cambridge, US.